Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 6 | 2022 | 89 | 2.170 |
Why?
|
| Glaucoma, Angle-Closure | 6 | 2020 | 14 | 2.000 |
Why?
|
| Glaucoma Drainage Implants | 5 | 2023 | 10 | 1.950 |
Why?
|
| Anterior Eye Segment | 8 | 2020 | 30 | 1.930 |
Why?
|
| Iris | 6 | 2017 | 65 | 1.890 |
Why?
|
| Tomography, Optical Coherence | 10 | 2020 | 523 | 1.690 |
Why?
|
| Intraocular Pressure | 16 | 2023 | 144 | 1.380 |
Why?
|
| Laser Coagulation | 4 | 2022 | 129 | 0.780 |
Why?
|
| Ocular Hypotension | 2 | 2023 | 4 | 0.760 |
Why?
|
| Ciliary Body | 3 | 2022 | 31 | 0.730 |
Why?
|
| Gonioscopy | 7 | 2020 | 10 | 0.660 |
Why?
|
| Trabecular Meshwork | 5 | 2018 | 11 | 0.650 |
Why?
|
| Ophthalmologic Surgical Procedures | 2 | 2016 | 87 | 0.600 |
Why?
|
| Iridectomy | 2 | 2020 | 6 | 0.580 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2017 | 19 | 0.570 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2018 | 38 | 0.550 |
Why?
|
| Eye Injuries | 1 | 2016 | 48 | 0.520 |
Why?
|
| Lasers | 1 | 2016 | 115 | 0.510 |
Why?
|
| Visual Acuity | 6 | 2018 | 824 | 0.500 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2016 | 214 | 0.460 |
Why?
|
| Cataract Extraction | 1 | 2016 | 216 | 0.440 |
Why?
|
| Tonometry, Ocular | 5 | 2018 | 31 | 0.380 |
Why?
|
| Herpesvirus 2, Human | 1 | 2011 | 13 | 0.370 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 26 | 0.370 |
Why?
|
| Eye Infections, Viral | 1 | 2011 | 28 | 0.360 |
Why?
|
| Herpes Simplex | 1 | 2011 | 55 | 0.360 |
Why?
|
| Eyelid Diseases | 1 | 2011 | 73 | 0.360 |
Why?
|
| Ocular Hypertension | 2 | 2023 | 26 | 0.340 |
Why?
|
| Iris Diseases | 2 | 2020 | 15 | 0.320 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2088 | 0.320 |
Why?
|
| Anterior Chamber | 2 | 2017 | 58 | 0.260 |
Why?
|
| Middle Aged | 15 | 2020 | 26459 | 0.260 |
Why?
|
| Humans | 28 | 2023 | 124398 | 0.220 |
Why?
|
| Aged | 13 | 2023 | 19479 | 0.220 |
Why?
|
| Retrospective Studies | 10 | 2023 | 16234 | 0.210 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2021 | 7 | 0.190 |
Why?
|
| Aniridia | 1 | 2021 | 12 | 0.190 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2021 | 34 | 0.180 |
Why?
|
| Ophthalmology | 2 | 2021 | 198 | 0.180 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2021 | 48 | 0.180 |
Why?
|
| Microscopy, Acoustic | 2 | 2020 | 17 | 0.180 |
Why?
|
| Coloboma | 1 | 2021 | 45 | 0.180 |
Why?
|
| Pupil Disorders | 1 | 2020 | 18 | 0.180 |
Why?
|
| Cerebellar Ataxia | 1 | 2021 | 65 | 0.180 |
Why?
|
| Female | 16 | 2020 | 66305 | 0.170 |
Why?
|
| Male | 15 | 2021 | 61025 | 0.170 |
Why?
|
| Introns | 1 | 2021 | 300 | 0.170 |
Why?
|
| Optic Nerve Diseases | 1 | 2021 | 89 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 2615 | 0.160 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2018 | 31 | 0.150 |
Why?
|
| Port-Wine Stain | 2 | 2021 | 6 | 0.150 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 168 | 0.150 |
Why?
|
| Anatomic Landmarks | 1 | 2018 | 17 | 0.150 |
Why?
|
| Equipment Failure | 1 | 2018 | 123 | 0.150 |
Why?
|
| Limbus Corneae | 1 | 2018 | 33 | 0.150 |
Why?
|
| Consensus | 1 | 2021 | 629 | 0.150 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 775 | 0.140 |
Why?
|
| Ophthalmologists | 1 | 2017 | 17 | 0.140 |
Why?
|
| Radiologists | 1 | 2017 | 44 | 0.140 |
Why?
|
| Lasers, Solid-State | 1 | 2017 | 17 | 0.140 |
Why?
|
| Bevacizumab | 1 | 2017 | 63 | 0.140 |
Why?
|
| Drainage | 1 | 2018 | 258 | 0.130 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 160 | 0.130 |
Why?
|
| Eye Abnormalities | 1 | 2017 | 106 | 0.130 |
Why?
|
| Young Adult | 4 | 2017 | 8979 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 240 | 0.130 |
Why?
|
| Students, Medical | 1 | 2020 | 356 | 0.130 |
Why?
|
| Demography | 1 | 2016 | 240 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2030 | 0.120 |
Why?
|
| Adolescent | 5 | 2017 | 19358 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 208 | 0.120 |
Why?
|
| Laser Therapy | 1 | 2017 | 250 | 0.120 |
Why?
|
| Telemedicine | 1 | 2020 | 438 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1264 | 0.110 |
Why?
|
| Intellectual Disability | 1 | 2021 | 1061 | 0.110 |
Why?
|
| Adult | 7 | 2020 | 29396 | 0.110 |
Why?
|
| Retinal Vein | 1 | 2013 | 12 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 3137 | 0.100 |
Why?
|
| Choroid Neoplasms | 1 | 2013 | 25 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1102 | 0.100 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2013 | 17 | 0.100 |
Why?
|
| Vascular Fistula | 1 | 2013 | 31 | 0.100 |
Why?
|
| ROC Curve | 3 | 2020 | 562 | 0.100 |
Why?
|
| Fluorescein Angiography | 1 | 2013 | 141 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1245 | 0.100 |
Why?
|
| Hemangioma | 1 | 2013 | 96 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2873 | 0.100 |
Why?
|
| Acyclovir | 1 | 2011 | 46 | 0.090 |
Why?
|
| Valine | 1 | 2011 | 107 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2020 | 1177 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2011 | 205 | 0.080 |
Why?
|
| Neuroimaging | 2 | 2021 | 340 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 5809 | 0.070 |
Why?
|
| Recurrence | 1 | 2011 | 1423 | 0.070 |
Why?
|
| Child | 3 | 2022 | 24528 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 1184 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2011 | 746 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2017 | 3068 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2016 | 6089 | 0.060 |
Why?
|
| Bimatoprost | 1 | 2023 | 2 | 0.050 |
Why?
|
| Cloprostenol | 1 | 2023 | 4 | 0.050 |
Why?
|
| Amides | 1 | 2023 | 83 | 0.050 |
Why?
|
| Ophthalmic Solutions | 1 | 2023 | 91 | 0.050 |
Why?
|
| Genotype | 2 | 2018 | 2552 | 0.050 |
Why?
|
| Eye | 1 | 2023 | 227 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3268 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1660 | 0.040 |
Why?
|
| Facies | 1 | 2021 | 156 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5107 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 100 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 228 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 2021 | 73 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 397 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2021 | 172 | 0.040 |
Why?
|
| Phenotype | 2 | 2021 | 4255 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2021 | 118 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2021 | 276 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3427 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 280 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 422 | 0.040 |
Why?
|
| Infant | 3 | 2021 | 12481 | 0.040 |
Why?
|
| Neurology | 1 | 2021 | 108 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 788 | 0.040 |
Why?
|
| Body Constitution | 1 | 2018 | 36 | 0.040 |
Why?
|
| Lasers, Semiconductor | 1 | 2017 | 9 | 0.040 |
Why?
|
| Argon Plasma Coagulation | 1 | 2017 | 4 | 0.040 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2017 | 24 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 122 | 0.030 |
Why?
|
| Visual Fields | 1 | 2018 | 133 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 719 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2017 | 147 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6470 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 1614 | 0.030 |
Why?
|
| Seizures | 1 | 2021 | 878 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 315 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2021 | 14085 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 725 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 411 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 709 | 0.030 |
Why?
|
| Phacoemulsification | 1 | 2017 | 236 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2022 | 12287 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 831 | 0.030 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2017 | 342 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 687 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1894 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3578 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2805 | 0.020 |
Why?
|
| Software | 1 | 2013 | 685 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8185 | 0.020 |
Why?
|
| United States | 1 | 2023 | 10773 | 0.020 |
Why?
|